Chest CT Using Low-concentration Iodine Contrast Media

Status Recruiting

Clinical Trial Summary

This study aims to evaluate the quality of images when low-concentration iodine contrast agents is used in chest CT with low tube voltage and if they can be used in routine imaging. The primary endpoint of the study was the quality of the image and comparison of chest CT by using low and conventional concentration iodine contrast agents with low tube voltage and chest CT by using the conventional concentration iodine contrast agents with the conventional tube voltage; The secondary endpoint is optimizing chest CT protocol using an iodine contrast agent.

Clinical Trial Description

With persistent advances in computed tomography (CT) technology, there is a need for continuous investigation and optimization of injection protocols. Intravenous contrast enhancement in CT is affected by various interacting factors, which can be roughly divided into 3 categories: patient, contrast medium and CT scanning. Over the last decade, evolutions in technology has resulted in faster CTs with improved temporal and spatial resolutions; newer techniques such as iterative reconstruction has enabled lower tube voltage (expressed in units of peak kiloVolt, kVp) and lower dose CTs with less noise and preserved image quality. As CT scanning is one of the major determinants of contrast enhancement at CT, such technological advances in CT can be assumed to have invariably caused alterations in the degree of contrast enhancement at CT. However, despite changes in CT scanning techniques, recommended contrast injection protocol for chest CT with enhancement (CECT), including concentration of iodine contrast material, have not changed over the last decade; for routine chest CECT, the use of 300-350 mgI/ml iodine contrast material has been recommended without definitely stating the precise reasons using that specific iodine concentration. Therefore, the aim of this study was to evaluate the image quality of low voltage chest CECT using LCCM(Low-Concentration Iodinated Contrast Media. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05967117
Study type	Interventional
Source	Seoul St. Mary's Hospital
Contact	Jung IM Jung, MD, PhD
Phone	+822-2258-1456
Email	jijung@catholic.ac.kr
Status	Recruiting
Phase	Phase 4
Start date	November 24, 2023
Completion date	November 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03572335` - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Recruiting	`NCT06088485` - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Terminated	`NCT03309358` - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis	Phase 1
Active, not recruiting	`NCT02504697` - DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
Completed	`NCT01443845` - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)	Phase 4
Terminated	`NCT00524095` - Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis	Phase 2
Completed	`NCT00210249` - Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Completed	`NCT00023114` - p450 Mediated Lung Toxicity	N/A
Recruiting	`NCT06056882` - Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules
Completed	`NCT03994848` - Incentive Spirometry Prehabilitation Study	N/A
Completed	`NCT00366509` - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Withdrawn	`NCT05100160` - Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)	Phase 3
Completed	`NCT03229473` - Fall Risk Assessment in COPD
Recruiting	`NCT04767074` - A Non-pharmacological Cough Control Therapy	N/A
Not yet recruiting	`NCT03899298` - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions	Phase 1
Completed	`NCT04996693` - On Dose Efficiency of Modern CT-scanners in Chest Scans	N/A
Recruiting	`NCT04996173` - Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis)	N/A
Completed	`NCT04601545` - The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method	N/A
Recruiting	`NCT03937583` - Screening for Cancer in Patients With Unprovoked VTE	Phase 4
Recruiting	`NCT02862418` - Imaging of Lungs With a New Type of Magnetic Resonance Imaging (MRI) Called UTE (Ultrashort Echo Time)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.